The present invention relates to a modification polymerization initiator and a method for preparing the same, and the modification polymerization initiator includes a derived unit from a compound represented by Formula 1 and may include various functional groups in a molecule, and thus, may initiate polymerization reaction and introduce a functional group into a polymer chain at the same time. In addition, the preparation method according to the present invention may prepare the modification polymerization initiator with high purity in high yield.

Phytol contained in watermelon sprouts is known to have a cancer cell growth inhibiting effect. However, there is a problem that an amount of phytol to be taken for exhibiting cancer cell growth inhabition is large.

A cancer cell growth inhibiting composition comprising at least one of compounds having a structure represented by Formula (1), Formula (2), Formula (6), Formula (7) or Formula (8), or a pharmaceutically acceptable salt thereof as main components has a higher cancer cell growth inhibiting effect than phytol.

##STR00001##

Phytol contained in watermelon sprouts is known to have a cancer cell growth inhibiting effect. However, there is a problem that an amount of phytol to be taken for exhibiting cancer cell growth inhabition is large.

A cancer cell growth inhibiting composition comprising at least one of compounds having a structure represented by Formula (1), Formula (2), Formula (6), Formula (7) or Formula (8), or a pharmaceutically acceptable salt thereof as main components has a higher cancer cell growth inhibiting effect than phytol.

##STR00001##

A compound has a perovskite type crystal structure containing A which is a monovalent cation, B which is a metal ion, and X which is a halide ion as components. The perovskite type crystal structure has a unit cell volume of 0.2000 nm.sup.3 or more and 0.2150 nm.sup.3 or less, an ionic radius of B of 0.7 Å or more and 1.4 Å or less, and an ionic radius of X of 0.5 Å or more and 2.5 Å or less.

The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX or Formula X and, the methods for the treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections.

The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX or Formula X and, the methods for the treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections.

The present disclosure discloses a quantum dot and a preparation method thereof, the method comprises a plurality of following steps: preparing a quantum dot solution; preparing an ion-containing organic ligand precursor; adding the ion-containing organic ligand precursor into the quantum dot solution, and making a surface-modification to the quantum dots, before obtaining the quantum dots having the surfaces modified; or providing a quantum dot solution; providing an ion-containing organic ligand precursor; mixing the ion-containing organic ligand precursor and the quantum dot solution, to make a ligand exchanging, before centrifuging and obtaining the quantum dots having the ligand exchanged.

The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX or Formula X and, the methods for the treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections.

The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX or Formula X and, the methods for the treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections.

The present invention relates to a modification polymerization initiator and a method for preparing the same, and the modification polymerization initiator includes a derived unit from a compound represented by Formula 1 and may include various functional groups in a molecule, and thus, may initiate polymerization reaction and introduce a functional group into a polymer chain at the same time.